The following is a summary of “Safety and Efficacy of a Novel, Variable-Sequenced, Long-Pulsed, 532-nm and 1,064-nm Laser With Cryogen Spray Cooling for Pigmented and Vascular Lesions,” published in the July 2023 issue of the Dermatologic Surgery by Wang et al.
Patients seek treatment for vascular and pigmented lesions frequently. Recently, a novel, variable-sequence, long-pulse, 532-nm, and 1,064-nm laser with cryogen spray cooling was created to increase treatment flexibility. A prospective clinical trial evaluated the safety and efficacy of a novel, variable-sequenced, long-pulsed, 532-nm and 1,064-nm laser with cryogen spray cooling (DermaV, Lutronic, South Korea). Participants with vascular and pigmented lesions were enrolled and treated with lasers.
About 23 participants with vascular lesions (39.1%), pigmented lesions (17.4%), or both (43.5%) were enrolled. The average age was 53.1 years, and 91.3% were female. Included were Fitzpatrick skin categories II through IV. Four of the subjects were also treated with a wavelength of 1,064 nm. In 94.7%, 92.1%, 84.2%, and 76.3% of cases, the correct before and after four blinded physicians selected photographs. 86.8% responded, indicating that three out of four reviewers concurred.
In 81.6%, 81.6%, 81.6%, and 76.3% of cases, the Global Aesthetic Improvement Scale exhibited improvement. There were no significant adverse events. Overall, 87.0% of respondents expressed satisfaction or satisfaction. A novel, variable-sequence, long-pulsed, 532-nm and 1,064-nm laser with cryogen spray cooling can enhance vascular and pigmented lesions safely and effectively.
Source: journals.lww.com/dermatologicsurgery/Abstract/2023/07000/Safety_and_Efficacy_of_a_Novel,.11.aspx
